A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT06614192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and change in disease activity of intravenously (IV) infused telisotuzumab adizutecan in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms and each treatment arm receives a different dose of telisotuzumab adizutecan. Up to approximately 60 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study at approximately 80 sites in 7 countries. Participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. The total study duration will be approximately 4 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Study identification
- NCT ID
- NCT06614192
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2024
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
- Last update posted
- Sep 22, 2026
2024 – 2027
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center /ID# 267875 | Duarte | California | 91010 | — |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 270655 | Irvine | California | 92618 | — |
| USC Norris Comprehensive Cancer Center /ID# 268131 | Los Angeles | California | 90033 | — |
| Lutheran Medical Center- Cancer Centers of Colorado /ID# 268175 | Golden | Colorado | 80401 | — |
| Smilow Cancer Center At Yale-New Haven /ID# 269125 | New Haven | Connecticut | 06511 | — |
| AdventHealth Orlando /ID# 267970 | Orlando | Florida | 32803 | — |
| Winship Cancer Institute of Emory University /ID# 266884 | Atlanta | Georgia | 30322 | — |
| St. Luke's Cancer Institute: Boise /ID# 268095 | Boise | Idaho | 83712 | — |
| Northwestern Medicine - Northwestern Memorial Hospital /ID# 268610 | Chicago | Illinois | 60611 | — |
| Hope And Healing Cancer Services /ID# 268541 | Hinsdale | Illinois | 60521 | — |
| Springfield Clinic - First /ID# 268666 | Springfield | Illinois | 62702 | — |
| Community Cancer Center North /ID# 267965 | Indianapolis | Indiana | 46250 | — |
| Hattiesburg Clinic /ID# 267860 | Hattiesburg | Mississippi | 39401 | — |
| Washington University /ID# 267872 | St Louis | Missouri | 63110 | — |
| Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 268185 | Billings | Montana | 59102 | — |
| Rutgers Cancer Institute of New Jersey /ID# 268056 | New Brunswick | New Jersey | 08901 | — |
| University of North Carolina Medical Center /ID# 266879 | Chapel Hill | North Carolina | 27514 | — |
| Duke University Medical Center /ID# 267966 | Durham | North Carolina | 27710 | — |
| Avera Cancer Institute - Sioux Falls /ID# 268074 | Sioux Falls | South Dakota | 57105 | — |
| West Cancer Center and Research Institute - Germantown /ID# 268619 | Germantown | Tennessee | 38138 | — |
| University of Texas - Southwestern Medical Center /ID# 268241 | Dallas | Texas | 75235 | — |
| The University of Texas MD Anderson Cancer Center /ID# 268098 | Houston | Texas | 77030 | — |
| Millennium Physicians /ID# 268400 | Houston | Texas | 77090 | — |
| University of Virginia /ID# 268108 | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06614192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2026 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06614192 live on ClinicalTrials.gov.